Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Evotec SE

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Evotec SE from 2014 to 2023. Over this period, United Therapeutics consistently outpaced Evotec SE in SG&A spending, with an average annual expense of approximately $394 million, compared to Evotec's $74 million. Notably, United Therapeutics saw a 27% increase in SG&A expenses from 2014 to 2023, peaking in 2022. Meanwhile, Evotec SE experienced a staggering 843% rise, reflecting its aggressive expansion strategy. This data underscores the contrasting financial strategies of these two industry players, with United Therapeutics maintaining steady growth and Evotec SE rapidly scaling its operations. Understanding these trends offers valuable insights into their strategic priorities and market positioning.